Q2 End Sparks Options Frenzy

Quarter-end has lit up the options market. Bears are doubling down while a handful of catalysts are driving unusual activity across biotech, consumer, and pharma.

SRPT is one of the most active names today. Sarepta Therapeutics is moving closer to FDA approval for its Duchenne muscular dystrophy treatments. Short interest sits at a heavy 30.6% of free float. Options expiries run through September, with near-term July contracts attracting attention as traders position around the regulatory timeline.

ABBV is drawing call-side interest after its Genmab lymphoma trial hit its primary endpoint. Analysts are flagging a bigger market opportunity. The July 20 and September 29 expiries stand out as non-standard dates — a sign of event-driven positioning. Short interest remains low at just 1.4%, suggesting most of the flow is bullish.

NKE faces a different setup. The sneaker giant heads into earnings this week with short interest at 5% of free float. Options chains run cleanly through August and September. Bears and bulls are both active heading into the print.

Elsewhere, a notable sweep hit Titan Mining — 1,000 August 21 $2.50 calls at $0.55, far above the 19 contracts of open interest. That kind of aggressive call sweep against thin open interest signals fresh directional bets ahead of its August earnings.

NVDA continues to carry the broadest options coverage in the market. It has expiries on nearly every day through July. Today's June 30 expiry is settling at the close — pinning risk is elevated into quarter-end.

Quarter-end flows, FDA catalysts, and upcoming earnings are all colliding. Watch SRPT and ABBV most closely. This is not financial advice.